Infection of macaques with simian HIV (SHIV) during concurrent pre-exposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) is associated with reduced acute plasma viremias and limited virus diversity, thus providing a unique model to assess long-term effects of acute antiretroviral treatment. Here, we investigated the effect of PrEP on acute SHIV DNA dynamics in peripheral blood mononuclear cells (PBMCs), and on the size of the persistent virus reservoir in lymphoid tissues.
Cell-associated SHIV DNA levels were measured in PBMCs during acute infection in 8 macaques infected during concurrent PrEP with FTC/TDF combination or single-agent tenofovir alafenamide fumarate (TAF). Macaques continued treatment with 1-2 weekly drug doses to model suboptimal drug exposure during undiagnosed HIV infection in humans. Peak SHIV DNA and area under the curve values (AUC) over 5 or 20 weeks, as well as RNA levels, were compared to the values seen in untreated SHIV infections (n = 10). SHIV DNA levels were also measured in lymphoid tissues collected from FTC/TDF or maraviroc PrEP breakthroughs after 1 year of infection.
PrEP breakthrough infections had reduced plasma RNA viremias relative to untreated infections both at peak and during the first 20 weeks of infection (p<0.005). SHIV DNA levels in PBMCs were also reduced in PrEP breakthrough infections both at peak and at week 5 (p = 0.022 and p = 0.043, respectively), but not after 20 weeks of infection. At 1 year, SHIV DNA reservoirs in lymphoid tissues were similar in size among macaques that received PrEP with FTC/TDF (median = 464 SHIV DNA copies/106 cells; range, 40-5,346), PrEP with maraviroc (median = 1088 copies/106 cells; range, 554-10,090), or placebo (median = 952 copies/106 cells; range, undetectable-24,668) (p > 0.05).
Antiviral drug activity due to PrEP limits acute SHIV replication but has only a transient effect on cell-associated DNA levels in PBMCs and lymphoid tissues. Our model suggests that suboptimal drug exposure in persons that are taking PrEP and become infected with HIV may not be sufficient to reduce the pool of HIV-infected cells, and that treatment intensification may be needed to sustain the virologic benefit from the PrEP regimen.